Link between disease status at 24 months and mortality in follicular lymphoma-Reference-Cited by-同舟云学术

Link between disease status at 24 months and mortality in follicular lymphoma

Published:2022-08-26 Issue:3 Volume:199 Page:458-462
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Rajamäki Aino¹²^ORCID,Hujo Mika³,Sund Reijo²,Prusila Roosa E. I.⁴^ORCID,Kuusisto Milla E. L.⁴⁵,Kuitunen Hanne⁶,Jantunen Esa²⁷,Mercadal Santiago⁸^ORCID,Sorigue Marc⁹,Sancho Juan‐Manuel⁹^ORCID,Kuittinen Outi²⁴¹⁰,Sunela Kaisa¹¹

Affiliation:

1. Department of Oncology Hospital Nova of Central Finland Jyväskylä Finland

2. Institute of Clinical Medicine, Faculty of Health Sciences University of Eastern Finland Kuopio Finland

3. School of Computing, Faculty of Science and Forestry University of Eastern Finland Kuopio Finland

4. Medical Research Center and Cancer and Translational Research Unit University of Oulu and Oulu University Hospital Oulu Finland

5. Department of Hematology Oulu University Hospital Oulu Finland

6. Department of Oncology Oulu University Hospital Oulu Finland

7. Department of Medicine Kuopio University Hospital Kuopio Finland

8. ICO‐Hospital Duran I Reynals L'Hospitalet Spain

9. Department of Hematology ICO‐Hospital Germans Trias i Pujol, IJC, UAB Barcelona Spain

10. Department of Oncology Kuopio University Hospital Kuopio Finland

11. Department of Oncology, Tays Cancer Center Tampere University Hospital Tampere Finland

Funder

Blood Disease Research Foundation

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.18423

Reference15 articles.

1. Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience

2. Trends in excess mortality in follicular lymphoma at a population level

3. Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry Study

4. Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Small sized centroblasts as poor prognostic factor in follicular lymphoma - Based on artificial intelligence analysis;Computers in Biology and Medicine;2024-08

2. Progression-free survival after front line, second line and third line in patients with follicular lymphoma treated in clinical practice;Acta Oncologica;2024-05-06

3. Prognostic value of the combination of volume, massiveness and fragmentation parameters measured on baseline FDG pet in high-burden follicular lymphoma;Scientific Reports;2024-04-05

4. Integrative genomic and transcriptomic analysis reveals genetic alterations associated with the early progression of follicular lymphoma;British Journal of Haematology;2023-07-16